Drug Trial Radar · NCT07923357
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
364
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind (with open-lable semaglutide 1.0 mg, active comparator), placebo-and active-controlled, parallel-group Phase 2 clinical trial aimed at evaluating the efficacy, safety and pharmacokinetic (PK) characteristics of SAL0150 tablets in subjects with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control after diet and exercise alone or after diet and exercise combined with stable-dose metformin monotherapy.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Type 2 Diabetes
- T2DM
Interventions
SAL0150 dose 1Drug
SAL0150 tablets, use as specified in the protocol
SAL0150 dose 2Drug
SAL0150 tablets,use as specified in the protocol
SAL0150 dose 2Drug
SAL0150 tablets, use as specified in the protocol
SAL0150 dose 3Drug
SAL0150 tablets, use as specified in the protocol
SAL0150 dose 3Drug
SAL0150 tablets, use as specified in the protocol
PlaceboDrug
Placebo
Semaglutide inject 1.0 mgDrug
Semaglutide inject, 1.0 mg once weekly, 15 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: Change From Baseline in HbA1c at Week 16(Baseline, Week 16)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.